Vistagen Partners With GATC Health to Apply Predictive AI to Drug Development

Bitget2026/10/20 12:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Vistagen entered a collaboration with GATC Health to apply predictive AI to its lead clinical-stage drug development programs.
GATC Health's Operon platform and Derisq predictive intelligence will inform study design, pipeline prioritization and resource allocation.
The collaboration supports a potential Phase 3 fasedienol study for social anxiety disorder, using the Liebowitz Social Anxiety Scale as primary efficacy endpoint.
Potential Phase 2 studies include itruvone for major depressive disorder and refisolone for menopausal hot flashes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610200830PRIMZONEFULLFEED9849133) on October 20, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Vistagen Partners With GATC Health to Apply Predictive AI to Drug Development

You may also like

Crypto prices